跳至主要内容
临床试验/DRKS00024503
DRKS00024503进行中(未招募)3 期

Continuous amnion infusion via an implanted catheter system in the case of classic preterm premature rupture of membranes (PPROM) with oligo- / anhydramnion between 22+ 0 and 26 + 0 weeks of gestation: a multicenter prospective controlled clinical study - Flush-Out-PPROM

niversitätsklinikum Halle Saale, Universitätsklinik und Poliklinik für Geburtshilfe und Pränatalmedizin Zentrum für Fetalchirurgie0 个研究点目标入组 19 人开始时间: 2021年3月4日最近更新:
适应症

试验速览

阶段
3 期
状态
进行中(未招募)
发起方
入组人数
19

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 one(—)
性别
Female

入选标准

  • •Pregnant women capable of giving consent between the 22 + 0 week of gestation to 26 + 0 week of pregnancy with classic PPROM and oligo- / anhydramnios
  • •Pregnant women aged =18 years
  • •Singleton pregnancies
  • •Completed RDS prophylaxis
  • •written consent for voluntary participation in the clinical trial

排除标准

  • •Occurrence of a single PPROM without leakage of amniotic fluid in the form of an oligo- / anhydramnion
  • •pre-PPROM
  • •Occurrence of a PPROM with oligo / anhydramnios before 20 + 0 and after 26 + 0 weeks of gestation
  • •PPROM more than 14 days ago
  • •CRP> 20 mgl / L
  • •known fetal chromosomal abnormalities
  • •Intrauterine drug application
  • •severe fetal malformations
  • •Signs of prematurity
  • •Signs of intrauterine infection or inflammation or both, especially triple I:
  • •o maternal fever of unknown origin (if the orally measured temperature is above 38.0 ° C
  • •AND ONE of the following:
  • •o fetal tachycardia over 160 beats per min. for> 10 min.
  • •o Maternal leukocytes> 15,000 / microliter without administration of corticosteroids
  • •o purulent fluoride from the cervix
  • •o maternal tachycardia> 100 bpm
  • •intrauterine fetal death
  • •Indication for termination of pregnancy, e.g. HELLP syndrome, pathological CTG, eclampsia, umbilical cord proplapse
  • •Cervical insufficiency (shortening of the cervix to less than 2.5 cm)
  • •Meconium finish
  • •IUGR <5 percentile with pathological Doppler
  • •Placenta previa
  • •(Partial) premature placenta detachment
  • •known maternal chronic infection with HIV, active Hep B, C
  • •Severe autoimmune diseases (e.g. rheumatic such as lupus e., Psoriasis) or immunosuppressive therapy due to the above-mentioned or hematological underlying diseases
  • •known multi-resistant infection / colonization
  • •any other medical or psychological impairment which, in the medical judgment, precludes participation in this study
  • •Persons accommodated in an institution on the basis of a court or official order (AMG §40, Paragraph 1, No. 4)
  • •Participation in another clinical trial at the same time or up to 30 days before inclusion (with the exception of observational studies and registry studies)

研究者

发起方
niversitätsklinikum Halle Saale, Universitätsklinik und Poliklinik für Geburtshilfe und Pränatalmedizin Zentrum für Fetalchirurgie

相似试验